ExPASy logo ExPASy Home page Site Map Search ExPASy Contact us Swiss-Prot
Notice: This page will be replaced with www.uniprot.org. Please send us your feedback!
Search for

UniProtKB/Swiss-Prot entry P08913


[Entry info] [Name and origin] [References] [Comments] [Cross-references] [Keywords] [Features] [Sequence] [Tools]

Note: most headings are clickable, even if they don't appear as links. They link to the user manual or other documents.
Entry information
Entry name ADA2A_HUMAN
Primary accession number P08913
Secondary accession numbers Q2I8G2 Q2XN99 Q86TH8 Q9BZK1
Integrated into Swiss-Prot on November 1, 1988
Sequence was last modified on February 1, 1996 (Sequence version 3)
Annotations were last modified on    September 23, 2008 (Entry version 105)
Name and origin of the protein
Protein name Alpha-2A adrenergic receptor
Synonyms Alpha-2A adrenoreceptor
Alpha-2A adrenoceptor
Alpha-2AAR
Alpha-2 adrenergic receptor subtype C10
Gene name
Name: ADRA2A
Synonyms: ADRA2R, ADRAR
From
Homo sapiens (Human) [TaxID: 9606] 
Taxonomy Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; Homo.
Protein existence 1: Evidence at protein level;
References
[1]
NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND PARTIAL PROTEIN SEQUENCE.
TISSUE=Platelet;
PubMed=2823383 [NCBI, ExPASy, EBI, Israel, Japan]
Kobilka B.K., Matsui H., Kobilka T.S., Yang-Feng T.L., Francke U., Caron M.G., Lefkowitz R.J., Regan J.W.;
"Cloning, sequencing, and expression of the gene coding for the human platelet alpha 2-adrenergic receptor.";
Science 238:650-656(1987).
[2]
NUCLEOTIDE SEQUENCE [GENOMIC DNA].
PubMed=2568356 [NCBI, ExPASy, EBI, Israel, Japan]
Fraser C.M., Arakawa S., McCombie W.R., Venter J.C.;
"Cloning, sequence analysis, and permanent expression of a human alpha 2-adrenergic receptor in Chinese hamster ovary cells. Evidence for independent pathways of receptor coupling to adenylate cyclase attenuation and activation.";
J. Biol. Chem. 264:11754-11761(1989).
[3]
SEQUENCE REVISION TO 333-365.
PubMed=2170371 [NCBI, ExPASy, EBI, Israel, Japan]
Guyer C.A., Horstman D.A., Wilson A.L., Clark J.D., Kragoe E.J. Jr., Limbird L.E.;
"Cloning, sequencing, and expression of the gene encoding the porcine alpha 2-adrenergic receptor. Allosteric modulation by Na+, H+, and amiloride analogs.";
J. Biol. Chem. 265:17307-17317(1990).
[4]
NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT LYS-251.
DOI=10.1074/jbc.M004550200; PubMed=10948191 [NCBI, ExPASy, EBI, Israel, Japan]
Small K.M., Forbes S.L., Brown K.M., Liggett S.B.;
"An Asn to Lys polymorphism in the third intracellular loop of the human alpha 2A-adrenergic receptor imparts enhanced agonist-promoted Gi coupling.";
J. Biol. Chem. 275:38518-38523(2000).
[5]
NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT LYS-251.
DOI=10.1073/pnas.0601345103; PubMed=16567612 [NCBI, ExPASy, EBI, Israel, Japan]
Small K.M., Brown K.M., Seman C.A., Theiss C.T., Liggett S.B.;
"Complex haplotypes derived from noncoding polymorphisms of the intronless alpha-2A-adrenergic gene diversify receptor expression.";
Proc. Natl. Acad. Sci. U.S.A. 103:5472-5477(2006).
[6]
NUCLEOTIDE SEQUENCE [MRNA].
Mao Z.-M., Tang K., Li B.-M., Jing N.-H.;
"Cloning and expression of human alpha-2A adrenergic receptor in SY5Y cells.";
Submitted (JUL-2000) to the EMBL/GenBank/DDBJ databases.
[7]
NUCLEOTIDE SEQUENCE [GENOMIC DNA].
Castellano M., Giacche' M., Rossi F., Rivadossi F., Perani C., Beschi M., Agabiti Rosei E.;
"A search for genetic variability in the human alpha-2 adrenergic receptor on chromosome 10.";
Submitted (AUG-2000) to the EMBL/GenBank/DDBJ databases.
[8]
NUCLEOTIDE SEQUENCE [GENOMIC DNA].
Liu L., Yuan L.;
"Human alpha-2A adrenergic receptor gene and the genotype of -1296 nucleotide and motionsickness.";
Submitted (APR-2001) to the EMBL/GenBank/DDBJ databases.
[9]
NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT LYS-251.
SeattleSNPs program for genomic applications;
Submitted (NOV-2005) to the EMBL/GenBank/DDBJ databases.
[10]
NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
DOI=10.1038/nature02462; PubMed=15164054 [NCBI, ExPASy, EBI, Israel, Japan]
Deloukas P., Earthrowl M.E., Grafham D.V., Rubenfield M., French L., Steward C.A., Sims S.K., Jones M.C., Searle S., Scott C., Howe K., Hunt S.E., Andrews T.D., Gilbert J.G.R., Swarbreck D., Ashurst J.L., Taylor A., Battles J., Bird C.P., Ainscough R., Almeida J.P., Ashwell R.I.S., Ambrose K.D., Babbage A.K., Bagguley C.L., Bailey J., Banerjee R., Bates K., Beasley H., Bray-Allen S., Brown A.J., Brown J.Y., Burford D.C., Burrill W., Burton J., Cahill P., Camire D., Carter N.P., Chapman J.C., Clark S.Y., Clarke G., Clee C.M., Clegg S., Corby N., Coulson A., Dhami P., Dutta I., Dunn M., Faulkner L., Frankish A., Frankland J.A., Garner P., Garnett J., Gribble S., Griffiths C., Grocock R., Gustafson E., Hammond S., Harley J.L., Hart E., Heath P.D., Ho T.P., Hopkins B., Horne J., Howden P.J., Huckle E., Hynds C., Johnson C., Johnson D., Kana A., Kay M., Kimberley A.M., Kershaw J.K., Kokkinaki M., Laird G.K., Lawlor S., Lee H.M., Leongamornlert D.A., Laird G., Lloyd C., Lloyd D.M., Loveland J., Lovell J., McLaren S., McLay K.E., McMurray A., Mashreghi-Mohammadi M., Matthews L., Milne S., Nickerson T., Nguyen M., Overton-Larty E., Palmer S.A., Pearce A.V., Peck A.I., Pelan S., Phillimore B., Porter K., Rice C.M., Rogosin A., Ross M.T., Sarafidou T., Sehra H.K., Shownkeen R., Skuce C.D., Smith M., Standring L., Sycamore N., Tester J., Thorpe A., Torcasso W., Tracey A., Tromans A., Tsolas J., Wall M., Walsh J., Wang H., Weinstock K., West A.P., Willey D.L., Whitehead S.L., Wilming L., Wray P.W., Young L., Chen Y., Lovering R.C., Moschonas N.K., Siebert R., Fechtel K., Bentley D., Durbin R.M., Hubbard T., Doucette-Stamm L., Beck S., Smith D.R., Rogers J.;
"The DNA sequence and comparative analysis of human chromosome 10.";
Nature 429:375-381(2004).
[11]
NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
TISSUE=PNS, and Testis;
DOI=10.1101/gr.2596504; PubMed=15489334 [NCBI, ExPASy, EBI, Israel, Japan]
The MGC Project Team;
"The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).";
Genome Res. 14:2121-2127(2004).
[12]
NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 77-209.
DOI=10.1016/0014-5793(91)80301-I; PubMed=1849485 [NCBI, ExPASy, EBI, Israel, Japan]
Chhajlani V., Rangel N., Uhlen S., Wikberg J.E.S.;
"Identification of an additional gene belonging to the alpha 2 adrenergic receptor family in the human genome by PCR.";
FEBS Lett. 280:241-244(1991).
[13]
MUTAGENESIS OF PHE-412.
PubMed=1678390 [NCBI, ExPASy, EBI, Israel, Japan]
Suryanarayana S., Daunt D.A., von Zastrow M., Kobilka B.K.;
"A point mutation in the seventh hydrophobic domain of the alpha 2 adrenergic receptor increases its affinity for a family of beta receptor antagonists.";
J. Biol. Chem. 266:15488-15492(1991).
[14]
MUTAGENESIS OF ASPARTIC ACID AND SERINE RESIDUES.
PubMed=1678850 [NCBI, ExPASy, EBI, Israel, Japan]
Wang C.-D., Buck M.A., Fraser C.M.;
"Site-directed mutagenesis of alpha 2a-adrenergic receptors: Identification of amino acids involved in ligand binding and receptor activation by agonists.";
Mol. Pharmacol. 40:168-179(1991).
[15]
PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-297; SER-298 AND SER-299, AND MASS SPECTROMETRY.
TISSUE=Epithelium;
DOI=10.1016/j.cell.2006.09.026; PubMed=17081983 [NCBI, ExPASy, EBI, Israel, Japan]
Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P., Mann M.;
"Global, in vivo, and site-specific phosphorylation dynamics in signaling networks.";
Cell 127:635-648(2006).
[16]
STRUCTURE BY NMR OF 118-149.
DOI=10.1021/bi015811+; PubMed=11888275 [NCBI, ExPASy, EBI, Israel, Japan]
Chung D.A., Zuiderweg E.R., Fowler C.B., Soyer O.S., Mosberg H.I., Neubig R.R.;
"NMR structure of the second intracellular loop of the alpha 2A adrenergic receptor: evidence for a novel cytoplasmic helix.";
Biochemistry 41:3596-3604(2002).
Comments
Copyright
Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms. Distributed under the Creative Commons Attribution-NoDerivs License.
Cross-references
Sequence databases
EMBL
M18415; AAA51664.1; -; Genomic_DNA.[EMBL / GenBank / DDBJ] [CoDingSequence]
M23533; AAA51665.1; -; Genomic_DNA.[EMBL / GenBank / DDBJ] [CoDingSequence]
AF281308; AAF91441.1; -; Genomic_DNA.[EMBL / GenBank / DDBJ] [CoDingSequence]
AF316894; AAK01634.1; -; Genomic_DNA.[EMBL / GenBank / DDBJ] [CoDingSequence]
DQ149926; AAZ73101.1; -; Genomic_DNA.[EMBL / GenBank / DDBJ] [CoDingSequence]
AF284095; AAK26743.1; -; mRNA.[EMBL / GenBank / DDBJ] [CoDingSequence]
AF262016; AAG00447.2; -; Genomic_DNA.[EMBL / GenBank / DDBJ] [CoDingSequence]
AY032736; AAK51162.1; -; Genomic_DNA.[EMBL / GenBank / DDBJ] [CoDingSequence]
DQ285607; ABB72683.1; -; Genomic_DNA.[EMBL / GenBank / DDBJ] [CoDingSequence]
AL158163; CAH72817.1; -; Genomic_DNA.[EMBL / GenBank / DDBJ] [CoDingSequence]
BC035047; AAH35047.1; -; mRNA.[EMBL / GenBank / DDBJ] [CoDingSequence]
BC050414; AAH50414.4; -; mRNA.[EMBL / GenBank / DDBJ] [CoDingSequence]
PIR A34169; A34169.
UniGene Hs.249159
3D structure databases
PDB
1HLL; NMR; -; A=118-149.[ExPASy / RCSB / EBI]
1HO9; NMR; -; A=118-149.[ExPASy / RCSB / EBI]
1HOD; NMR; -; A=118-149.[ExPASy / RCSB / EBI]
1HOF; NMR; -; A=118-149.[ExPASy / RCSB / EBI]
Detailed list of linked structures.
PDBsum 1HLL; -.
1HO9; -.
1HOD; -.
1HOF; -.
ModBase P08913.
Protein family/group databases
GPCRDB P08913; ADA2A_HUMAN.
PTM databases
PhosphoSite P08913; -.
Organism-specific databases
H-InvDB HIX0025918; -.
HGNC HGNC:281; ADRA2A.
GenAtlas ADRA2A.
MIM 104210; gene. [NCBI / EBI]
PharmGKB PA35; -.
GeneCards P08913.
Gene expression databases
ArrayExpress P08913; -.
CleanEx HS_ADRA2A; -.
GermOnline ENSG00000150594; Homo sapiens.
Ontologies
GO
GO:0005887; Cellular component: integral to plasma membrane (traceable author statement from ProtInc).
GO:0004938; Molecular function: alpha2-adrenergic receptor activity (traceable author statement from ProtInc).
GO:0015459; Molecular function: potassium channel regulator activity (traceable author statement from ProtInc).
GO:0030036; Biological process: actin cytoskeleton organization (traceable author statement from ProtInc).
GO:0000187; Biological process: activation of MAPK activity (traceable author statement from ProtInc).
GO:0006928; Biological process: cell motion (traceable author statement from ProtInc).
GO:0007186; Biological process: G-protein coupled receptor protein signaling pathway (traceable author statement from ProtInc).
GO:0007194; Biological process: negative regulation of adenylate cyclase activity (traceable author statement from ProtInc).
GO:0008284; Biological process: positive regulation of cell proliferation (traceable author statement from ProtInc).
GO:0007266; Biological process: Rho protein signal transduction (traceable author statement from ProtInc).
QuickGo view.
Family and domain databases
InterPro IPR001946; Adren_rcpt_A2A.
IPR015695; Adren_rcpt_A2A/B/C.
IPR002233; Adrnrgc_rcpt.
IPR000276; GPCR_Rhodpsn.
IPR017452; GPCR_Rhodpsn_supfam.
Graphical view of domain structure.
PANTHER PTHR19266:SF56; Alpha-2A_Recept; 1.
Pfam PF00001; 7tm_1; 1.
Pfam graphical view of domain structure.
PRINTS PR01103; ADRENERGICR.
PR00558; ADRENRGCA2AR.
PR00237; GPCRRHODOPSN.
PROSITE PS00237; G_PROTEIN_RECEP_F1_1; 1.
PS50262; G_PROTEIN_RECEP_F1_2; 1.
PROSITE graphical view of domain structure (profiles).
BLOCKS P08913.
Genome annotation databases
Ensembl ENSG00000150594; Homo sapiens. [Contig view]
KEGG hsa:150; -.
Phylogenomic databases
HOGENOM P08913; -.
HOVERGEN P08913; -.
Other
DrugBank DB00321; Amitriptyline.
DB00182; Amphetamine.
DB00964; Apraclonidine.
DB00865; Benzphetamine.
DB00217; Bethanidine.
DB00484; Brimonidine.
DB00575; Clonidine.
DB04840; Debrisoquin.
DB00633; Dexmedetomidine.
DB00449; Dipivefrin.
DB00751; Epinastine.
DB00696; Ergotamine.
DB00800; Fenoldopam.
DB00629; Guanabenz.
DB00226; Guanadrel Sulfate.
DB01170; Guanethidine.
DB01018; Guanfacine.
DB04948; Lofexidine.
DB00968; Methyldopa.
DB06148; Mianserin.
DB00370; Mirtazapine.
DB00368; Norepinephrine.
DB00935; Oxymetazoline.
DB00692; Phentolamine.
DB00397; Phenylpropanolamine.
DB00852; Pseudoephedrine.
DB00697; Tizanidine.
DB00656; Trazodone.
DB01392; Yohimbine.
SOURCE ADRA2A; Homo sapiens.
GPCRDB-Snakes P08913.
ProtoNet P08913.
UniRef View cluster of proteins with at least 50% / 90% / 100% identity.
Keywords
3D-structure; Cell membrane; Direct protein sequencing; G-protein coupled receptor; Glycoprotein; Lipoprotein; Membrane; Palmitate; Phosphoprotein; Polymorphism; Receptor; Transducer; Transmembrane.
Features
SEVIEWER logo Feature table viewer FT aligner logo Feature aligner
KeyFrom   To Length Description FTId
CHAIN   1   450  450     Alpha-2A adrenergic receptor. PRO_0000069080
TOPO_DOM   1    33  33     Extracellular (Potential). 
TRANSMEM   34    59  26     1 (Potential). 
TOPO_DOM   60    70  11     Cytoplasmic (Potential). 
TRANSMEM   71    96  26     2 (Potential). 
TOPO_DOM   97   106  10     Extracellular (Potential). 
TRANSMEM   107   129  23     3 (Potential). 
TOPO_DOM   130   149  20     Cytoplasmic (Potential). 
TRANSMEM   150   173  24     4 (Potential). 
TOPO_DOM   174   192  19     Extracellular (Potential). 
TRANSMEM   193   217  25     5 (Potential). 
TOPO_DOM   218   374  157     Cytoplasmic (Potential). 
TRANSMEM   375   399  25     6 (Potential). 
TOPO_DOM   400   406  7     Extracellular (Potential). 
TRANSMEM   407   430  24     7 (Potential). 
TOPO_DOM   431   450  20     Cytoplasmic (Potential). 
SITE   113   113  1     Implicated in ligand binding. 
SITE   200   200  1     Implicated in catechol agonist binding and receptor activation. 
SITE   204   204  1     Implicated in catechol agonist binding and receptor activation. 
MOD_RES   297   297        Phosphoserine. 
MOD_RES   298   298        Phosphoserine. 
MOD_RES   299   299        Phosphoserine. 
LIPID   442   442        S-palmitoyl cysteine (By similarity). 
CARBOHYD   10    10        N-linked (GlcNAc...) (Potential). 
CARBOHYD   14    14        N-linked (GlcNAc...) (Potential). 
DISULFID   106   188        By similarity. 
VARIANT   251   251  1     N -> K (rare polymorphism; frequency in Caucasians 0.004 and in African-Americans 0.05; 40% increase in agonist-promoted Gi coupling; dbSNP:rs1800035 [NCBI]). VAR_014957 
MUTAGEN   79    79        D->N: No change in binding affinity. eliminates guanine nucleotide-sensitive agonist binding. 
MUTAGEN   113   113        D->N: No binding to yohimbine. Increase in adenylate cyclase activity. 
MUTAGEN   130   130        D->N: Lower affinity for agonists. Eliminates guanine nucleotide-sensitive agonist binding. 
MUTAGEN   200   200        S->A: Lower affinity for agonists. No change in guanine nucleotide-sensitive agonist binding. 
MUTAGEN   204   204        S->A: Lower affinity for agonists. Reduced guanine nucleotide-sensitive agonist binding. 
MUTAGEN   412   412        F->N: 350-fold reduced affinity for alpha-2 antagonist yohimbine, 3000-fold increase for beta-antagonist alprenolol. 
CONFLICT   104   104        A -> T (in Ref. 1; AAA51664). 
CONFLICT   124   124        L -> P (in Ref. 12). 
CONFLICT   157   157        V -> C (in Ref. 1; AAA51664). 
CONFLICT   333   365        PRRGPGATGIGTPAAGPGEERVGAAKASRWRGR -> RGAGRGRRGSGRRLQGRGRSASGLPRRRAGAGG (in Ref. 1; AAA51664 and 2; AAA51665). 
CONFLICT   368   368        R -> L (in Ref. 1; AAA51664). 
HELIX   119   128  10      
HELIX   130   139  10      
HELIX   140   142  3      
Sequence information
Length: 450 AA [This is the length of the unprocessed precursor] Molecular weight: 48957 Da [This is the MW of the unprocessed precursor] CRC64: A703CF262F04E8AC [This is a checksum on the sequence]
        10         20         30         40         50         60 
MGSLQPDAGN ASWNGTEAPG GGARATPYSL QVTLTLVCLA GLLMLLTVFG NVLVIIAVFT 

        70         80         90        100        110        120 
SRALKAPQNL FLVSLASADI LVATLVIPFS LANEVMGYWY FGKAWCEIYL ALDVLFCTSS 

       130        140        150        160        170        180 
IVHLCAISLD RYWSITQAIE YNLKRTPRRI KAIIITVWVI SAVISFPPLI SIEKKGGGGG 

       190        200        210        220        230        240 
PQPAEPRCEI NDQKWYVISS CIGSFFAPCL IMILVYVRIY QIAKRRTRVP PSRRGPDAVA 

       250        260        270        280        290        300 
APPGGTERRP NGLGPERSAG PGGAEAEPLP TQLNGAPGEP APAGPRDTDA LDLEESSSSD 

       310        320        330        340        350        360 
HAERPPGPRR PERGPRGKGK ARASQVKPGD SLPRRGPGAT GIGTPAAGPG EERVGAAKAS 

       370        380        390        400        410        420 
RWRGRQNREK RFTFVLAVVI GVFVVCWFPF FFTYTLTAVG CSVPRTLFKF FFWFGYCNSS 

       430        440        450 
LNPVIYTIFN HDFRRAFKKI LCRGDRKRIV 

P08913 in FASTA format

View entry in original UniProtKB/Swiss-Prot format
View entry in raw text format (no links)
Report form for errors/updates in this UniProtKB/Swiss-Prot entry

BLAST logo BLAST submission on ExPASy/SIB
or at NCBI (USA)
Tools Sequence analysis tools: ProtParam, ProtScale, Compute pI/Mw, PeptideMass, PeptideCutter, Dotlet (Java)
PROSITE logo ScanProsite, MotifScan SWISS-MODEL Submit a homology modeling request to SWISS-MODEL
NPSA logo NPSA Sequence analysis tools

ExPASy logo ExPASy Home page Site Map Search ExPASy Contact us Swiss-Prot
 Hosted by ch flag SIB Switzerland Mirror sites: Australia  Brazil  Canada  China  Korea
Notice: This page will be replaced with www.uniprot.org. Please send us your feedback!